Geron could have a tougher time than it anticipated at tomorrow’s FDA advisory committee meeting for myelodysplastic syndromes (MDS) drug candidate imetelstat. A briefing document (PDF) published by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results